

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

### CHECKLIST OF RESPONSIBILITIES FOR SCIENTIFIC EDITORS

Manuscript page	number (With	nout Figures):_	25	Rate:	6.2	CNY	per	pag	ge
	•	· , -					-		_

Editing Fee: 155 CNY

Figure count: 2 Figure handling time: 35 min Rate: 1 CNY per min

Editing Fee: 35 CNY

XML and PDF converting time: 40 min Rate: 1 CNY per min

Editing Fee: 40 CNY

Manuscript word count: 6442

**Total Editing Fee:** 222 CNY

		Comments
Item No.	Specific items for verification	Yes=[Y]
		No= [N]
	General Information of the Manuscript	
	Name of journal: World Journal of Clinical Oncology	
	Manuscript NO.: 67608	
	Column: Minireviews	
	Title: Immunotherapy combinations and chemotherapy sparing	
	schemes in first line non-small cell lung cancer	
1	Authors: María Sereno, Oliver Higuera, Patricia Cruz Castellanos,	[Y ]
	Sandra Falagan, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes	
	and Felipe Couñago	
	Reviewer code: 05402718	
	First decision: 2021-07-16 05:51	
	Scientific Editor: Man Liu	
	Date of signature:11/22/2021(month/day/year)	



2

# Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

### Editorial Office's Comments

Science Editor: The general information for the manuscript is as follows: Manuscript No.: 67608 Journal: World Journal of Clinical Oncology Title: Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer Manuscript Type: Minireviews 1 Scientific quality: The manuscript presents the results of the main articles reporting on immunotherapy combinations, with or without chemotherapy, focusing principally on efficacy and toxicity data. The convenience of adding shorter chemotherapy regimens versus the standard 4-cycle regimens to immunotherapy doublets is discussed. The topic is within the scope of the WJG. (1) Classification: Grade C; (2) Summary of the Peer-Review Report: The authors reviewed immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancers. Although there is some interesting, but the manuscript needs improvement before considering publication; (3) Format: There are 3 tables; (4) References: A total of 23 references are cited, including 9 references published in the last 3 years; (5) Self-cited references: There is no self-cited references; (6) References recommendations: The authors have the right to refuse

to cite improper references recommended by the peer reviewer(s),

especially those published by the peer reviewer(s) him/herself

(themselves). If the authors find the peer reviewer(s) request for the

authors to cite improper references published by him/herself

(themselves), please send the peer reviewer's ID number to

[ Y]



# Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

editorialoffice@wjgnet.com. The Editorial Office will close and remove the peer reviewer from the F6Publishing system immediately. 2 Language evaluation: Classification: Grade B . A language editing certificate issued was provided. 3 Academic norms and rules: The authors provided the Biostatistics Review Certificate, the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement, and the Institutional Review Board Approval Form. Written informed consent was waived. No academic misconduct was found by the Google/Bing search. 4 Supplementary comments: No financial support was obtained for the study. The topic has not previously been published in the WJG. 5 Issues raised: (1)Introduction is simple, please also add some information about the basic information of NSCLC and the current immunotherapy for NSCLC. Two key reviews are recommended for you, PMID: 33653420 and PMID: 33643442. (2) The basic writing needs to be improved. For example, in the introduction, Anti-PD-L1/PD-1 and anti-CTLA-4 should use full name in the first time. Authors should revise it throughout the draft. (3)"although in the d- IT the median OS of 11.9 months was shorter than that obtained with CT", why have highlight information. What is "the d-IT"? Please carefully check the manuscript. (4)The authors must put the p values to all the tables describing the OS, PFS in different clinical trials. (5) The challenge of current Immunotherapy combinations and chemotherapy in NSCLC should be added. (6)A schematic diagram should be provided about how PD-1/PDL-1



**Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com

	interact with immune cells to combat NSCLC. This is important.	
	(7) The language is needed to be improved. 8. In table 1 and table 2,	
	the more information should be provided. Abstract: at line 64, define	
	ER (estrogen receptor) like in the introduction. Many of the	
	abbreviations appear for the first time in the abstract, thus what it is	
	stand-for needs to be written in the abstract. The statistical method	
	written in the abstract not consistent with Method section line 155	
	and Result line 181 (intraclass or interclass?) 6 Re-Review: Not	
	required. 7 Recommendation: Conditional acceptance.	
	Company Editor-in-Chief: I have reviewed the Peer-Review	
	Report, full text of the manuscript, and the relevant ethics	
	documents, all of which have met the basic publishing requirements	
	of the World Journal of Clinical Oncology, and the manuscript is	
	conditionally accepted. I have sent the manuscript to the author(s)	
	for its revision according to the Peer-Review Report, Editorial	
	Office's comments and the Criteria for Manuscript Revision by	
	Authors.	
3	The fixed headings are copied.	[ ]
	The title concisely summarizes the main topic of the study and is	
	not too long (no more than 18 words). Words such as 'exploration',	
4	'research', 'analysis', 'observation', and 'investigation' are avoided.	[Y ]
	The title does not start with 'The' and does not include any Arabic	
	numbers or uncommon abbreviations.	
5	A short running title is provided (no more than 6 words).	[Y]
	The authors' full family (sur)names and full/abbreviated first	
6	names are listed on the title page and are consistent with those	[ Y]
	listed in the signed BPG Copyright License Agreement form.	
	noted in the digited by a copyright election agreement form.	



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

7	The 'Author contributions' passage describes the specific contribution(s) made by each author. The author's names are listed in the following format: full family (sur)name followed by abbreviated first and middles names.  e.g., "Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research study; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents and analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the manuscript. All authors	[ ]
8	have read and approve the final manuscript."  The 'Supported by' statement describes the source(s) of financial support and includes the corresponding identification number(s) and program ID(s) if available, and contains no spelling errors.	[N ]
9	The 'Corresponding author' passage provides the corresponding author's full first and family (sur)names, abbreviated title (e.g., MD, PhD), affiliated institute's name and complete postal address (including zip code) and e-mail (written in all lowercase), and contains no spelling errors.	[Y ]
10	The Manuscript Tracking information ( <i>i.e.</i> , Received, Peer review started, First decision, Revised, Accepted, Article in press, and Published online) are provided along with the corresponding editor and date for each item, and contain no spelling errors.	[ Y]
11	The Abstract section is formatted according to the article-specific style (structured <i>vs</i> unstructured) and word count thresholds, as follows:  Commentary, Frontier, Diagnostic Advances, Medical Ethics, Minireview, Review, Therapeutics Advances, and Topic Highlight: Non-structured abstract that is no less than 200 words.  Field of Vision, Case Report and Letter to the Editor:	[Y]



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://	www.wjgnet.com/
----------	-----------------

	Non-structured abstract that is no less than 150 words.	
	Research articles: Structured abstract with subsections for AIM (no	
	more than 20 words); METHODS (no less than 80 words); RESULTS	
	(no less than 120 words); and CONCLUSION (no more than 26	
	words).	
	The 'Key words' list provides 5-10 keywords that reflect the main	
12	content of the study. The first letter of each keyword is capitalized,	[Y ]
	and each keyword is separated by a semicolon.	
	The "citation" contains authors' names and manuscript title. The	
	name of the first author should be typed in bold letters; the family	
	(sur) name of all authors should be typed with the first letter	
	capitalized, followed by their abbreviated first and middle initials.	
13	For example, an article by Jae Moon Yoon, Ki Young Son, Chun Sick	[ Y]
	Eom, Daniel Durrance, Sang Min Park will be written as Yoon JM,	
	Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes	
	mellitus increases the risk of gastric cancer: A meta-analysis. World J	
	Gastroenterol 2019; In press	
	The 'Core tip' provides a summary (less than 100 words) of the	
14	study that outlines the most innovative and important arguments	[ N ]
14	and core contents of the paper and will serve to effectively attract	[Y ]
	readers.	
	The 'INTRODUCTION' section clearly describes the relevant	
	background information for the study. Only the most relevant and	
	current (within the past 5 years) literature is cited, with the	
15	exception of rare instances of seminal literature citations. All	
	technical terms and/or abbreviations are explained and/or defined,	[ Y]
	with the full name of abbreviations given upon first appearance in	
	the text and the abbreviation presented in parentheses [i.e.,	
	"computed tomography (CT)"]. First-person pronouns (e.g., 'I',	
	'we') are used appropriately to clearly indicate the work performed	



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	by the author(s). When weaknesses of previous studies are described in the text to highlight the innovations related to the current study, the information is presented carefully.	
16	The 'MATERIALS AND METHODS' section clearly and accurately describes all materials and methods used to obtain the data presented in the article and is adequate for a reader to repeat the study.	[ N]
17	The 'RESULTS' section concisely describes the observational and experimental results. Representative data and data that have scientific significance are emphasized. Data is presented in either the text, a table or figure ( <i>i.e.</i> , chart, diagram, graph or image), but is not repeated among each. Information presented in the tables and figures clearly describes the trends, meaning, and inferences. Results described in textual form are accurate, concise and clear.	[ N]
18	Statistical symbols are accurate. Statistical significance is expressed as ${}^aP < 0.05$ , ${}^bP < 0.01$ ( $P > 0.05$ usually does not need to be denoted). If there are other series of $P$ values, ${}^cP < 0.05$ and ${}^dP < 0.01$ are used, and a third series of $P$ values is expressed as ${}^cP < 0.05$ and ${}^fP < 0.01$ . Statistical data is expressed as mean $\pm$ SD or mean $\pm$ SE.	[ N]



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

19	The 'DISCUSSION' section (1) describes the main purpose and hypothesis of the study; (2) summarizes the most important results; (3) illustrates and explains the results (but does not simply repeat the data) and draws conclusions or inferences based on the results; (4) points out the limitations of the study and their impact on the	[Y ]
	results, as well as proposes further advice on future research topic(s) or direction(s); and (5) describes the theoretical significance and practical value of the findings.	
20	The 'ACKNOWLEDGEMENTS' section expresses gratitude to any individuals or organizations for technical support ( <i>i.e.</i> , providing instrumentation, equipment or experimental materials, and/or assistance in experimental work), non-technical services ( <i>i.e.</i> , useful inspiration, suggestions, guidance, or review), and/or any other auxiliary work.	[ N]
21	The 'ARTICLE HIGHLIGHTS' section provides comments for original articles in accordance with the specified format.	[ N]
22	The 'REFERENCES' section lists the references in the Vancouver style. This style uses Arabic numeral in-text citations based on the order of the first appearance of a source in the text. For citations where the author's name is indicated in the text, a superscript number should be placed following the name ( <i>i.e.</i> , "Pang <i>et al</i> "). For citations where no author is indicated, a superscript number should be placed at the end of the sentence. Respective examples are: "Ma <sup>[1]</sup> reported", "Pan <i>et al</i> <sup>[2-5]</sup> indicated"; "PCR has a high sensitivity <sup>[6,9]</sup> ." No superscript numbers are used when the reference number is described in the text; for example, "The experimental method used has been described in reference [8]." The style of reference citations in tables is the same as that in the text ( <i>e.g.</i> , Pan <i>et al</i> <sup>[2-5]</sup> , please see reference [8]).	[ Y]



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

	Journal references have been verified to ensure that there are no	
	duplicate references and that the PMID numbers are correct. For	
	references not yet included in PubMed: the name of Chinese	
23	journals is spelled out using Chinese Pinyin, with the first letter of	[Y ]
23	each word capitalized (e.g., Shijie Huaren Xiaohua Zazhi); the name of	[1]
	journals in other languages are listed according to indexing	
	information retrieved from Google. Book references are presented	
	with all the information relevant to the electronic version.	
	The number of cited references is appropriate for the article type, as	
	follows:	
24	Commentary: no less than 50;	F 2/3
24	Review: no less than 100;	[ Y]
	Article: no less than 30/26;	
	Case Report and Letter to the Editor: no less than 1.	
	The ethics-related statements are provided in accordance with the	
25	manuscript type (e.g., Manuscript NoInstitutional review board	[ Y]
	statement, Manuscript NoAnimal care and use statement, etc.).	
	The names of the peer reviewers and the scientific editor are present	
26	at the end of the paper (e.g., P-Reviewer: Hugot D S-Editor: Wang	[ Y]
	JL).	
	The order and numerical labeling of tables and figures is consistent	
	with their appearance and presentation in the text. Symbols in	
	tables (e.g., +, -, $\times$ , $\div$ , *) correctly correspond to the definitions in the	
27	footnotes. Only one legend is provided for each multi-panel figure	[V ]
27	consisting of color graphs, black and white graphs, or line graphs	[Y ]
	that depicts data of the same theme. For example: Figure 1	
	Pathological changes in atrophic gastritis tissue before and after	
	treatment. A:; B:; C:; D:; E:; F:	
20	Split pictures include flow charts, line graphs, histograms, and	[Y ]
28	graphs including text. Unsplit pictures include meta-analysis	



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	diagrams, PCR amplification curves, and survival curves.	
29	The author(s) highlighted the changes made to the manuscript	[Y ]
	according to the peer-reviewers' comments.	r- 1
30	The responses to the peer-reviewers' comments are consistent with	[ Y]
30	the changes made to the manuscript.	[ 1]
	The revised manuscript is provided (file name: Manuscript	
	NoReview; <i>e.g.</i> , 870- Review).	
21	The letter of peer-reviewers' comments is provided (file name:	I 3/1
31	Manuscript NoPeer-review(s); e.g., 870-Peer-review(s)).	[ Y]
	The response letter is provided (file name: Manuscript	
	NoAnswering reviewers; <i>e.g.</i> , 870-Answering reviewers).	
	The related ethics and relevant documents are provided, such as (1)	
	Approved grant application form(s) or funding agency copy of any	
	approval document(s) (file name: Manuscript NoGrant application	
	form(s)); (2) Biostatistics review certificate (file name: Manuscript	
	NoBiostatistics statement); (3) Conflict-of-interest statement (file	
	name: Manuscript NoConflict-of-interest statement); (4) Clinical	
	trial registration statement (file name: Manuscript NoClinical trial	
32	registration statement); (5) Institutional review board approval form	[Y ]
	or document (file name: Manuscript NoInstitutional review board	
	statement); (6) Institutional animal care and use committee	
	approval form or document (file name: Manuscript	
	NoInstitutional animal care and use committee statement), and (7)	
	Signed informed consent form(s) or document(s) (file name:	
	Manuscript NoInformed consent statement).	
	All authors signed the BPG Copyright license agreement form (file	
33	name: Manuscript NoCopyright license agreement; e.g.,	[Y ]
	870-Copyright license agreement).	
	The language certificate provided by authors who are non-native	
34	speakers of English meets the BPG requirements (file name:	[ Y]
	of amount of angular model and an of requirements (the faulte)	



**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

	NO. 1.17 T. 100 1. 170 T. 170		
	Manuscript NoLanguage certificate; <i>e.g.</i> , 870-Language certificate).		
	The photos licensed in the Agreement for Use of Personal Photos		
35	are consistent with those in the paper (file name: Manuscript	[ N]	
33	NoAgreement for use of personal photos; e.g., 870-Agreement for	[ 11]	
	use of personal photos).		
	This document (Checklist of Responsibilities for Scientific Editors)		
36	has been saved under the file name: manuscript NoScientific	[Y ]	
	editor work list (e.g., 870-Scientific editor work list).		
	A CrossCheck investigation (an effective tool for detecting unoriginal		
	content, enabling our editors to preserve the journal's integrity and		
	the authors' copyright) has been performed for the manuscript via		
	the website: http://www.ithenticate.com/. The results document		
	contains the following information for the manuscript: "Name of		
37	journal", "Manuscript No.", "Columns", "Title" and "Author list".	[ Y]	
	The Figure of the CrossCheck results is saved in JPEG format (.jpg) at		
	1440 × 680 pixel resolution. The PDF of the <i>CrossCheck</i> results has		
	been saved under the file name: manuscript No CrossCheck report		
	(e.g., 870-CrossCheck report). The Google searches have also been		
	performed to further ensure publication of original content.		
20	The text of the manuscript is typed in Book Antiqua font, 12 pt, with	[ ] 1	
38	1.5 line spacing.	[Y ]	
	The primary responsibilities of our scientific editors include carefull	y checking the	
	entire manuscript and all accompanying materials for: (1) error	rs in spelling.	
Responsibilities			
of scientific	grammar, punctuation and wording; (2) suitability of tables, figures, figure data and		
editors	legends; (3) accurate and appropriate presentation of symbols (e.g. +, -, ×, ÷, %, *) in		
	tables and figures; and (4) complete and comprehensive revision of the manuscript		
	according to the reviewers' comments.		
	I .		



# Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

## Publication process

Manuscript reception and registration→Initial review by scientific editor→Peer review→End of peer review→First round of meeting evaluation→To be accepted→Revision by the author(s)→Second round of meeting evaluation→To be accepted/revised/rejected-Final review by the Editor-in-Chief (final quality control for academic content and language quality)→Final acceptance and charging of publication fee-Language editing-Production-Proofreading by scientific editor→Proofreading by deputy editor→Final review by Editor-in-Chief→Release of online open-access papers in electronic form on the BPG website-Release of online papers on PubMed Central-Delivery of high-quality PDF reprints to the author(s) $\rightarrow$ End of the publication process.